Tasmar

FDA Public Health Advisory

Tasmar (tolcapone), is a C.O.M.T. inhibitor and is used to treat symptoms associated with Parkinson's disease. First approved in January 1998, in October the maker issued a warning stating, in part, "The company advises of new warnings in the labeling for Tasmar (tolcapone), a COMT inhibitor indicated as an adjunct to levodopa and carbidopa for the treatment of Parkinson's disease. These new warnings pertain to reports of severe, potentially life-threatening cases of severe hepatocellular injury.

Acute Liver Failure

People who experience acute liver failure become critically ill in a matter of days, with most cases resulting in the need for a liver transplant or even death. Drug-induced liver injury has become the number one cause of this rare syndrome. It's also the leading reason that drugs are removed from the market or require restricted use and special monitoring of patients.

Possible Tamoxifen Side Effects Lawsuit

If you or a family member have taken Tasmar and have experienced any side effects, particularly liver damage, you may be entitled to compensation.

Register your Tasmar Complaint

If you feel you qualify for damages or remedies that might be awarded in this possible lawsuit, please click the link below to submit your complaint.